Rosenbloom AL. The physiology of growth. Ann Nestlé. 2007;65:97–108.Google Scholar
de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 1992;255:306–312.PubMedCrossRefGoogle Scholar
Campbell GS. Growth-hormone signal transduction. J Pediatr. 1997;131(suppl.):S42–S44.PubMedCrossRefGoogle Scholar
Rinderknech E, Humbel RE. The amino acid sequence of human insulin like growth factor I and its structural homology with proinsulin. J Biol Chem. 1978;253:2769–2772.Google Scholar
Rinderknech E, Humbel RE. Primary structure of human insulin like growth factor II. FEBS Lett. 1978;89:283–287.CrossRefGoogle Scholar
Baxter RG, Binoux MA, Clemmons DR, et al. Recommendations for nomenclature of the insulin-like growth factor binding proteins superfamily. J Clin Endocrinol Metab. 1998;83:3213.PubMedCrossRefGoogle Scholar
Domené HM, Bengolea SV, Jasper HG, Boisclair YR. Acid-labile subunit deficiency: phenotypic similarities and differences between human and mouse. J Endocrinol Invest. 2005;28(5 suppl.):43–46.PubMedGoogle Scholar
Collett-Solberg PF, Cohen P. Genetics, chemistry, and function of the IGF/IGFBP system. Endocrine. 2000;12:121–136.PubMedCrossRefGoogle Scholar
Woods KA, Camacho-Hübner C, Savage MO, Clark AJL. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med. 1996;335:1363–1367.PubMedCrossRefGoogle Scholar
Walenkamp MJ, Karperien M, Pereira AM, et al. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab. 2005;90:2855–2284.PubMedCrossRefGoogle Scholar
Abuzzahab MJ, Schneider A, Goddard A, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med. 2003;349:2211–2222.PubMedCrossRefGoogle Scholar
Kawashima Y, Kanzaki S, Yang F, et al. Mutation at cleavage site of insulin like growth factor receptor in a short stature child born with intrauterine growth retardation. J Clin Endocrinol Metab. 2005;90:4679–4687.PubMedCrossRefGoogle Scholar
Walenkamp MJE, van der Kamp HJ, Pereira AM, et al. A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin like growth factor I receptor. J Clin Endocrinol Metab. 2006;91:3062–3070.PubMedCrossRefGoogle Scholar
Inagaki K, Tiulpakov A, Rubtsov P, et al. A familial insulin like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization. J Clin Endocrinol Metab. 2007;92:1542–1548.PubMedCrossRefGoogle Scholar
Walenkamp MJE, de Muinck Keizer-Schrama SMPF, de Mos M, et al. Successful long-term growth hormone therapy in a girl with haploinsufficiency of the insulin like growth factor-I receptor due to a terminal 15q26.2->qter deletion detected by multiplex ligation probe amplification. J Clin Endocrinol Metab. 2008;93:2421–2425.PubMedCrossRefGoogle Scholar
Hwa V, Camacho-Hübner C, Little BM, et al. Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. Horm Res. 2007;68:218–224.PubMedCrossRefGoogle Scholar
Giudice LC, de Zegher F, Gargosky SE, et al. Insulin like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth. J Clin Endocrinol Metab. 1995;80:1548–1555.PubMedCrossRefGoogle Scholar
Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Pollock BH. Growth in GH insensitivity. Trends Endocrinol Metab. 1994;5:296–303.PubMedCrossRefGoogle Scholar
Isaksson OG, Lindahl A, Nilsson A, Isgaard J. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev. 1987;6:426–438.Google Scholar
Daughaday WH, Rotwein P. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev. 1989;10:68–91.PubMedCrossRefGoogle Scholar
Fan Y, Menon RK, Cohen P, et al. Liver-specific deletion of the growth hormone receptor (GHR): effects on growth, growth mediators and body composition. Presented at: Pediatric Academic Societies Meeting; May 3, 2008; Honolulu, Hawaii.
McDonald A, Williams RM, Regan FM, Semple RK, Dunger DB. IGF-I treatment of insulin resistance. Eur J Endocrinol. 2007;157:S51–S56.PubMedCrossRefGoogle Scholar
Kemp SE, Thrailkill KM. SomatoKine: is there a use in treating growth disorders? Curr Opin Investig Drugs. 2005;6:373–377.PubMedGoogle Scholar
Guler HP, Zapf J, Froesch ER. Short-term metabolic effects and half-lives of intravenously administered insulin-like growth factor I in healthy adults. N Engl J Med. 1987;317:137–140.PubMedGoogle Scholar
Rosenbloom AL, Ongley JP. Serum calcium phosphorus and magnesium decrement during oral glucose tolerance testing: alteration in pre-clinical and overt diabetes mellitus in childhood. In: Catin M, Selig M, eds. Magnesium in Health and Disease. Jamaica, NY: Spectrum Publishers Inc.; 1980: 297–304.Google Scholar
Guler H-P, Schmid C, Zapp J, Froesch ER. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci U S A. 1989;86:2868–2872.PubMedCrossRefGoogle Scholar
Vaccarello MA, Diamond FBJr., Guevara-Aguirre J, et al. Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. J Clin Endocrinol Metab. 1993;77:273–280.PubMedCrossRefGoogle Scholar
Rosenbloom AL. IGF-I treatment of growth hormone insensitivity. In: Rosenfeld RG, Roberts CT, eds. The IGF System: Molecular Biology, Physiology, and Clinical Applications. Totowa, NJ: Humana Press; 1999:739–769.Google Scholar
Guevara-Aguirre J, Vasconez O, Martinez V, et al. A randomized double-blind, placebo-controlled trial of safety and efficacy of recombinant insulin-like growth factor-I in children with growth hormone 0. J Clin Endocrinol Metab. 1995;80:1393–1398.PubMedCrossRefGoogle Scholar
Crosnier H, Gourmelen M, Prëvot C, Rappaport R. Effects of nutrient intake on growth, insulin-like growth factors, and their binding proteins in a Laron-type dwarf. J Clin Endocrinol. 1993;6:248–250.CrossRefGoogle Scholar
Wilson KF, Fielder PJ, Guevara-Aguirre J, et al. Long-term effects of insulin-like growth factor (IGF)-I treatment on serum IGFs and IGF binding proteins in adolescent patients with growth hormone receptor deficiency. Clin Endocrinol. 1995;42:399–407.CrossRefGoogle Scholar
Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Rosenfeld RG. Two year treatment of growth hormone receptor deficiency (GHRD) with recombinant insulin-like growth factor-I in 22 children: comparison of two dosage levels and to GH treated GH deficiency. J Clin Endocrinol Metab. 1997;82:629–633.PubMedCrossRefGoogle Scholar
Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Ped Endocrinol Metab. 1995;8:149–158.Google Scholar
Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res. 1999;51:128–134.PubMedCrossRefGoogle Scholar
Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. GH Insensitivity Syndrome Collaborative Group. Long-term treatment with recombinant IGF-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrin Metab. 2007;92:902–910.CrossRefGoogle Scholar
Camacho-Hubner C, Underwood LE, Yordam N, et al. Once daily rhIGF-I/rhIGFBP3 treatment improves growth velocity in children with severe primary IGF-I deficiency: results of a multicenter clinical trial. Presented at: 88th Annual Meeting of The Endocrine Society; June 24–27, 2006; Boston, MA, 2006. Abstract OR 40-1.
Sjögren K, Liu JL, Blad K, et al. Liver-derived insulin-like growth factor-I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A. 1999;96:7088–7092.PubMedCrossRefGoogle Scholar
Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor-I. Proc Natl Acad Sci U S A. 1999;96:7324–7329.PubMedCrossRefGoogle Scholar
Hwa V, Haeusler G, Pratt KL, et al. Total absence of functional acid labile subunit, resulting in severe insulin like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab. 2006;91:1826–1831.PubMedCrossRefGoogle Scholar
Domené HM, Bengolea SV, Martínez AS, et al. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med. 2004;92:570–577.CrossRefGoogle Scholar
Domené HM, Scaglia P, Lteif A, et al. Phenotypic effects of null and haploinsufficiency of acid labile subunit in a family with two novel IGFALS gene mutations. J Endocrinol Metab. 2007;92:4444–4450.CrossRefGoogle Scholar
Camacho-Hübner C, Rose S, Preece MA, et al. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. J Clin Endocrinol Metab. 2006;91:1246–1253.PubMedCrossRefGoogle Scholar
Clark RG. Recombinant insulin like growth factor-I as a therapy for IGF-I deficiency in renal failure. Pediatr Nephrol. 2005;20:290–294.PubMedCrossRefGoogle Scholar
Rosenbloom AL. Is there a role for recombinant insulin-like growth factor-I (rhIGF-I) in the treatment of idiopathic short stature? Lancet. 2006;368:612–616.PubMedCrossRefGoogle Scholar
Long-term treatment with rhIGF-I in GHIS. Available at: www.clinicaltrials.gov/ct2/show/NCT00571727?term=tercica&rank=10. Accessed December 20, 2008.
Treatment of children and adolescents with growth failure associated with primary insulin like growth factor I (IGF-I) deficiency. Available at: www.clinicaltrials.gov/ct2/show/NCT00330668?term=tercica&rank=2. Accessed December 20, 2008.
Prepubertal children with growth failure associated with primary insulin like growth factor I (IGFI) deficiency. Available at: www.clinicaltrials.gov/ct2/show/NCT00572156?term=tercica&rank=3. Accessed December 20, 2008.
Recombinant human insulin like growth factor (rhIGF-I) treatment of short stature associated with IGF-I deficiency. Available at: www.clinicaltrials.gov/ct2/show/NCT00125190?term=tercica&rank=7. Accessed December 20, 2008.
rhGH and rhIGF-I combination therapy in children with short stature associated with IGF-I deficiency. Available at: www.clinicaltrials.gov/ct2/show/NCT00572156?term=tercica&rank=4. Accessed December 20, 2008.
Fielder PJ, Mortensen DL, Mallet P, Carlsson B, Baxter RC, Clark RG. Differential long-term effects of insulin-like growth factor-I (IGF-I), growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats. Endocrinology. 1996;137:1913–1920.PubMedCrossRefGoogle Scholar
Rosenbloom AL. Hot topic. IGF-I treatment of diabetes. Pediatr Diabetes. 2001;2:123–130.PubMedCrossRefGoogle Scholar
Genentech discontinues IGF-I drug development effort in diabetes [press release]. San Francisco, CA: Genentech, Inc.; September 5, 1997. Available at: www.gene.com/gene/news/press-releases/display.do?method=detail&id=4842. Accessed December 20, 2008.
Cusi K, DeFronzo R. Recombinant human insulin like growth factor I treatment for one week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab. 2000;85:3077–3084.PubMedCrossRefGoogle Scholar
Study of recombinant human insulin like growth factor I in patients with severe insulin resistance. Available at: www.clinicaltrials.gov/ct2/show/NCT00004419?term=IGF-I&rank=44. Accessed December 20, 2008.
Insulin like growth factor I (IGF-I) and amyotrophic lateral sclerosis (ALS) trial. Available at: www.clinicaltrials.gov/ct2/show/NCT00035815?term=IGFI&rank=2. Accessed December 20, 2008.
A 48-week (24 week baseline followed by a 24 week treatment) phase II pilot study of the tolerability and effect/efficacy of subcutaneously administered insulin like growth factor -1 (rhIGF) (CEP-151) in multiple sclerosis (MS) Patients. Available at: www.clinicaltrials.gov/ct2/show/NCT00001669?term=IGF-I&rank=66. Accessed December 20, 2008.
Effects of SomatoKine (Iplex) (rhIGF-I/rhIGFBP-3) in myotonic dystrophy type 1 (iPLEX). Available at: www.clinicaltrials.gov/ct2/show/NCT00233519?term=insmed&rank=2. Accessed December 20, 2008.
Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008;71:1770–1775.PubMedCrossRefGoogle Scholar
Ezzat VA, Duncan ER, Wheatcroft SB, Kearney MT. The role of IGF-I and its binding proteins in the development of type II diabetes and cardiovascular disease. Diab Obes Metab. 2008;10:198–211.CrossRefGoogle Scholar
Marleau S, Mulumba M, Lamontagne D, Ong H. Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies. Cardiovasc Res. 2006;69:26–35.PubMedCrossRefGoogle Scholar
Differential effects of rhGH versus rhIGF-I on cardiovascular risk factors. Available at: www.clinicaltrials.gov/ct2/show/NCT00684957?term=tercica&rank=9. Accessed December 20, 2008.
Boonen S, Rosen C, Bouillon R, et al. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab. 2002;87:1593–1599.PubMedCrossRefGoogle Scholar
Descriptive study of recombinant human insulin like growth factor for osteoporosis in Werner syndrome. Available at: www.clinicaltrials.gov/ct2/show/NCT00004815?term=IGF-I&rank=189. Accessed December 20, 2008.
Effects of rhIGF-I on bone metabolism in adolescent girls with anorexia nervosa. Available at: www.clinicaltrials.gov/ct2/show/NCT00720122?term=IGFI&rank=87. Accessed December 20, 2008.
Smith LEH. Can we restore aspects of the in utero environment in premature infants to prevent disease? Pediatrics. 2004;114:491.PubMedCrossRefGoogle Scholar
Hansen-Pupp I, Engström E, Niklasson A, et al. Fresh-frozen plasma as a source of exogenous insulin like growth factor i in the extremely preterm infant. J Clin Endocrinol Metab. 2008; Nov 11 [Epub ahead of print].
Effect of Increlex™ on children with Crohn disease. Available at: www.clinicaltrials.gov/ct2/show/NCT00764699?term=tercica&rank=12. Accessed December 20, 2008.
Treatment for growth failure in patients with X-linked severe combined immunodeficiency: phase 2 study of insulin-like growth factor-1. Available at: www.clinicaltrials.gov/ct2/show/NCT00490100?term=IGF-I&rank=4. Accessed December 20, 2008.
Evaluation the growth factors (IGF-1,IGFBP-3 and HGH) in patients with chronic liver disease. Available at: www.clinicaltrials.gov/ct2/show/NCT00679692?term=IGF-I&rank=20. Accessed December 20, 2008.
IGF-I therapy in patients with cystic fibrosis. Available at: http://clinicaltrials.gov/ct2/show/NCT00566241
. Accessed January 25, 2009.
Dudgeon WD, Phillips KD, Carson JA, et al. Counteracting muscle wasting in HIV-infected individuals. HIV Med. 2006;7:299–310.PubMedCrossRefGoogle Scholar
Hollis ERII, Lu P, Blesch A, Yuszynski MH. IGF-I gene delivery promotes cortical spinal neuronal survival but not regeneration after adult CNS injury. Exp Neurol. 2009;215:53–59.PubMedCrossRefGoogle Scholar
Carro E, Trejo JL, Gerber A, et al. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol Aging. 2005;27:1250–1257.PubMedCrossRefGoogle Scholar
Iwai K, Nakagawa T, Endo T, et al. Cochlear protection by local insulin-like growth factor-1 application using biodegradable hydrogel. Laryngoscope. 2006;116:529–533.PubMedCrossRefGoogle Scholar
Rosenbloom AL, Francke U, Rosenfeld RG, Guevara-Aguirre J. Growth hormone receptor deficiency in Ecuador. J Clin Endocrinol Metab. 1999;84:4436–4443.PubMedCrossRefGoogle Scholar
Vasconez O, Martinez V, Martinez AL, et al. Heart rate increase in patients with growth hormone receptor deficiency treated with insulin-like growth factor I. Acta Paediatr. 1994;399:137–139.CrossRefGoogle Scholar
Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N. Long-term IGF-I treatment of children with Laron syndromic increases adiposity. Growth Horm IGF Res. 2006;16:61–64.PubMedCrossRefGoogle Scholar
Torjusen E, Calderon J, Rivkees SA. Anaphylactic reaction to recombinant insulin-like growth factor-I. J Pediatr Endocrinol Metab. 2008;21:381–384.PubMedGoogle Scholar
Samani AA, Yakar S, LeRoith D, Brodt P. The role of IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007; 28:20–47.PubMedCrossRefGoogle Scholar
Perry JK, Emerald BS, Mertani HC, Lovie PE. The oncogenic potential of growth hormone. Growth Horm IGF Res. 2006;16:277–289.PubMedCrossRefGoogle Scholar